Cargando…
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial
BACKGROUND: Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r+3TC) versus triple therapy using LPV/r plus two nucleoside reverse transcriptase inhibi...
Autores principales: | Tan, Darrell H. S., Rolon, Maria Jose, Figueroa, Maria Ines, Sued, Omar, Gun, Ana, Kaul, Rupert, Raboud, Janet M., Szadkowski, Leah, Hull, Mark W., Walmsley, Sharon L., Cahn, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6730918/ https://www.ncbi.nlm.nih.gov/pubmed/31490959 http://dx.doi.org/10.1371/journal.pone.0221653 |
Ejemplares similares
-
Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017) -
Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study
por: Cahn, Pedro, et al.
Publicado: (2014) -
Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy
por: Tsoukas, Christos, et al.
Publicado: (2013) -
Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy
por: Tan, Darrell H. S., et al.
Publicado: (2015) -
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)